Agomab Therapeutics NV is a Belgium-based biotech company. The Company is engaged in the development of antibodies for damaged tissues. It develops novel treatments that aim to preserve and restore organ function in fibrotic diseases. It also develops growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. The Company targets growth factors and modulates related molecular pathways through monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. It works with academic institutions and industrial partners to develop treatment options for patients.
企業コードAGMB
会社名Agomab Therapeutics NV
上場日- -
最高経営責任者「CEO」- -
従業員数- -
証券種類Depository Receipt
決算期末- -
本社所在地Posthoflei 1 box 6
都市
証券取引所NASDAQ OMX - NASDAQ BASIC
国Belgium
郵便番号2600
電話番号
ウェブサイト
企業コードAGMB
上場日- -
最高経営責任者「CEO」- -
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし